Enhanced Anti-lymphoma Activity of CAR19-iNKT Cells Underpinned by Dual CD19 and CD1d Targeting

被引：121

作者：

Rotolo, Antonia ^{[1
]}

Caputo, Valentina S. ^{[1
]}

Holubova, Monika ^{[1
,2
]}

Baxan, Nicoleta ^{[3
]}

Dubois, Olivier ^{[3
]}

Chaudhry, Mohammed Suhail ^{[1
]}

Xiao, Xiaolin ^{[1
]}

Goudevenou, Katerina ^{[1
]}

Pitcher, David S. ^{[1
]}

Petevi, Kyriaki ^{[1
]}

Kachramanoglou, Carolina ^{[4
]}

Iles, Sandra ^{[5
]}

Naresh, Kikkeri ^{[1
]}

Maher, John ^{[6
]}

Karadimitris, Anastasios ^{[1
]}

机构：

[1] Imperial Coll London, Dept Med, Ctr Haematol, London, England

[2] Charles Univ Prague, Med Fac Pilsen, Biomed Ctr, Alej Svobody 76, Plzen 32300, Czech Republic

[3] Imperial Coll London, Dept Med, Biol Imaging Ctr, London, England

[4] Imperial Coll Healthcare NHS Trust, Dept Neuroradiol, London, England

[5] Hammersmith Hosp, Northwest London Pathol, Cellular Pathol, London, England

[6] Kings Coll London, Guys Hosp, Sch Canc & Pharmaceut Sci, London, England

来源：

CANCER CELL | 2018年 / 34卷 / 04期

关键词：

KILLER T-CELLS; INVARIANT NKT CELLS; CHRONIC LYMPHOCYTIC-LEUKEMIA; VERSUS-HOST-DISEASE; B-CELLS; ADOPTIVE IMMUNOTHERAPY; ALPHA-GLYCOSYLCERAMIDE; DISTINCT SUBSETS; GENE-EXPRESSION; RECEPTOR;

D O I：

10.1016/j.ccell.2018.08.017

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Chimeric antigen receptor anti-CD19 (CAR19)-T cell immunotherapy-induced clinical remissions in CD19(+) B cell lymphomas are often short lived. We tested whether CAR19-engineering of the CD1d-restricted invariant natural killer T (iNKT) cells would result in enhanced anti-lymphoma activity. CAR19-iNKT cells co-operatively activated by CD1d- and CAR19-CD19-dependent interactions are more effective than CAR19-T cells against CD1d-expressing lymphomas in vitro and in vivo. The swifter in vivo anti-lymphoma activity of CAR19-iNKT cells and their enhanced ability to eradicate brain lymphomas underpinned an improved tumor-free and overall survival. CD1D transcriptional de-repression by all-trans retinoic acid results in further enhanced cytotoxicity of CAR19-iNKT cells against CD19(+) chronic lymphocytic leukemia cells. Thus, iNKT cells are a highly efficient platform for CAR-based immunotherapy of lymphomas and possibly other CD1d-expressing cancers.

引用

页码：596 / +

页数：26

共 50 条

[21] CD19/BCMA Dual-Targeting CAR-T Cells Generated by Co-Transduction for the Treatment of Non-Hodgkin Lymphoma
Bachiller, Mireia
Barcelo, Nina
Dobano-Lopez, Celia
Rodriguez-Garcia, Alba
Castellsague, Joan
Gimenez-Alejandre, Marta
Alserawan, Leticia
Delgado, Julio
Espanol-Rego, Marta
Pascal, Mariona
Juan, Manel
Perez-Galan, Patricia
Urbano-Ispizua, Alvaro
Guedan, Sonia
MOLECULAR THERAPY, 2023, 31 (04) : 122 - 122
[22] Tandem CD19/CD22 Dual Targets CART Cells Therapy Acquires Superior CR Rate Than CD19 CAR-T Cells: A Case Controlled Study
Cui, Wei
Zhang, Xinyue
Dai, Haiping
Cui, Qingya
Song, Baoquan
Wu, Depei
Tang, Xiaowen
Yin, Jia
Li, Zheng
BLOOD, 2020, 136
[23] PD-1 blockade improves the cytotoxicity of tolerogenic CD19-CAR-iNKT cells towards CD19+malignancies
Moraes Ribeiro, E.
Wesle, A.
Secker, K. A.
Schairer, R.
Neuber, B.
Schmitt, A.
Keppeler, H.
Korkmaz, F.
Lengerke, C.
Schneidawind, C.
Schmitt, M.
Schneidawind, D.
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 171 - 172
[24] Low Levels of Neurologic Toxicity with Retained Anti-Lymphoma Activity in a Phase I Clinical Trial of T Cells Expressing a Novel Anti-CD19 CAR
Brudno, Jennifer
Hartman, Steven
Lam, Norris
Stroncek, David F.
Rossi, John M.
Shen, Yueh-wei
Xue, Allen
Bot, Adrian
Kanakry, Jennifer A.
Pavletic, Steven Z.
Mikkilineni, Lekha
Roschewski, Mark
Dean, Robert M.
Rose, Jeremy J.
Patel, Rashmika
Hansen, Brenna
Rosenberg, Steve A.
Gress, Ronald E.
Kochenderfer, James N.
BLOOD, 2018, 132
[25] EPIGENETIC TARGETING OF CD1D INCREASES ANTI-TUMOUR INKT ACTIVITY IN NON-SMALL CELL LUNG CANCER
Dockry, Eilis F.
JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S373 - S373
[26] How to integrate CD19 specific chimeric antigen receptor T cells with other CD19 targeting agents in diffuse large B-cell lymphoma?
de Ramon Ortiz, Carmen
Wang, Sisi
Stathis, Anastasios
Bertoni, Francesco
Zenz, Thorsten
Novak, Urban
Simonetta, Federico
HEMATOLOGICAL ONCOLOGY, 2024, 42 (01)
[27] Cd19-car-inkt cell activity is enhanced by pd-1 checkpoint inhibition while preventing alloreactivity
Ribeiro, E. Moraes
Nitulesco, A. -M.
Schairer, R.
Keppeler, H.
Korkmaz, F.
Neuber, B.
Schneidawind, C.
Schmitt, M.
Schneidawind, D.
BONE MARROW TRANSPLANTATION, 2022, 57 (SUPPL 1) : 149 - 149
[28] CD19-CAR-INKT CELL ACTIVITY IS ENHANCED BY PD-1 CHECKPOINT INHIBITION WHILE PREVENTING ALLOREACTIVITY
Ribeiro, E. Moraes
Nitulescu, A.
Schairer, R.
Secker, K.
Keppeler, H.
Neuber, B.
Schneidawind, C.
Schmitt, M.
Schneidawind, D.
CYTOTHERAPY, 2022, 24 (05) : S125 - S125
[29] PD-1 CHECKPOINT INHIBITION IMPROVES FUNCTIONALITY OF TOLEROGENIC CD19-CAR-INKT CELLS AGAINST CD19+MALIGNANCIES
Ribeiro, Emmanuelle Moraes
Wesle, Anton
Secker, Kathy-Ann
Schmitt, Anita
Keppeler, Hildegard
Schneidawind, Corina
Schmitt, Michael
Schneidawind, Dominik
BONE MARROW TRANSPLANTATION, 2023, 58 (SUPP1) : 226 - 226
[30] Targeting CAR T Resistance Due to CD19 Loss with CD79b-Specific CAR T Cells in B-Cells Malignancies
Chu, Fuliang
Weng, Jinsheng
Kuang, Shao-Qing
Cheng, Xiaoyun
Cao, JingJing
Liu, Jingwei
Karri, Swathi
Reddy, Adithi
Neelapu, Sattva S.
BLOOD, 2018, 132

← 1 2 3 4 5 →